Guided Therapeutics (GTHP) Free Cash Flow Growth (3y) (2014 - 2025)
Guided Therapeutics (GTHP) Free Cash Flow Growth (3y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 129.05 Bn | 126.17 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 68.63 Bn | 67.18 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 48.43 Bn | 44.76 Bn | 1.29 Bn | -27.72% |
| 6 | Dexcom | 28.36 Bn | 27.24 Bn | 750.30 Mn | 77.20% |
| 7 | GE HealthCare Technologies | 28.14 Bn | 25.85 Bn | 1.98 Bn | -29.89% |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 24.25 Bn | 21.12 Bn | 2.07 Bn | -0.27% |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | 5.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.24% |
| Sep 30, 2025 | 23.10% |
| Jun 30, 2025 | 22.71% |
| Mar 31, 2025 | -19.70% |
| Dec 31, 2024 | -66.23% |
| Sep 30, 2024 | 12.95% |
| Jun 30, 2024 | 32.51% |
| Mar 31, 2024 | 32.21% |
| Dec 31, 2023 | -0.50% |
| Sep 30, 2023 | 7.05% |
| Jun 30, 2023 | -0.93% |
| Mar 31, 2023 | 1.99% |
| Dec 31, 2022 | -18.99% |
| Sep 30, 2022 | -38.75% |
| Jun 30, 2022 | -24.87% |
| Mar 31, 2022 | -1.24% |
| Dec 31, 2021 | 34.10% |
| Sep 30, 2021 | -12.69% |
| Jun 30, 2021 | -49.33% |
| Mar 31, 2021 | 5.96% |